The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
EHC Video on European Recommendations for Haemophilia Treatment +
Please view this timely video from the European Haemophilia Consortium on "European recommendations for the treatment of haemophilia and other bleeding disorders."Read More
PPTA Hosts Successful 2014 Plasma Protein Forum +
Over 250 attendees from 10 countries gathered together in Washington, DC to attend the 2014 Plasma Protein Forum on June 26th and 27th.Read More
Ontario Holds its Parliamentary Elections +
On June 12, Ontario held its Parliamentary Elections resulting in an absolute majority for the Liberal Party. The first order of business for the Legislature will be the adoption of a provincial budget. Party leaders expect to re-convene in early July.Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly.
Read the current issue.